Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma

• Status: Recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a pilot study to assess a new methodology developed for High Grade Glioma (HGG). FMISO PET (Fluoromisonidazole-PET) allows researchers to study whether tumor cells lack oxygen (hypoxia). FLT PET (Fluorodeoxythymidine-PET) allows researchers to study the increase in the number of cells as a result of cell growth and cell division (proliferation). Tumors that have low oxygen levels and/or are dividing fast shall resist to standard cancer treatment. The study will compare FMISO PET and FLT PET imaging techniques with molecular biomarkers of hypoxia, angiogenesis, and cellular proliferation in tissue. proliferation).This information could help researchers develop new treatment techniques to better treat cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Weill Medical College of Cornell University
• Collaborator: William Rhodes Center for Glioblastoma
• Treatments: Alovudine

Criteria

Inclusion Criteria:

• Male or female ≥ 18 years of age

• Documentation of a suspected HGG diagnosis based on clinical and MRI findings

Exclusion Criteria:

• Pregnant or breastfeeding

• Contraindications to receiving Positron Emission Tomography (PET) imaging (e.g. claustrophobia)